Caixin
Caixin Global – Latest China News & Headlines

Home >

TRENDING
Popular WeChat Account Valued at 2 Billion Yuan Snapped Up By Education Firm
'Missiles' Are Shooting Trouble Into China’s Underground Lending Market
Shaanxi Anti-Corruption Official Under Investigation — for Corruption
LATEST
Here Are the First Companies Hoping to List on China's High-Tech Board
Police Officer Took 42 Million Yuan in Bribes to Change Drivers’ Traffic Records
Historic Car Maker Enters New-Energy Ride-Hailing Business
Urban Chinese More Inclined to Save Than Spend in Q1: PBOC Data
China’s Tesla Rival Denies Reports of Mass Layoffs, Inflated Sales Figures
Chemical Blast in East China Kills 47, Seriously Injures 90
Tencent Quarterly Profit Sags, to Pay Dividend
Former Tencent AI Chief to Head New Sinovation-Backed Hong Kong Lab
U.S. Trade Delegation to Visit Beijing on March 28-29, China Says
The Fall of a Mysterious Private Villa in a Protected Wilderness Area in China
More Party Discipline Inspections Are Coming, With Focus on Central Government Institutions
China to Draft Value-Added Tax Law This Year
China Construction Bank Names New President
China High-Level Economic Forum to Focus on Opening Up
China Telecom to Invest 9 Billion Yuan in 5G This Year
People’s Daily Head Leaves for High-Level Position at Beijing’s Liaison Office in Hong Kong
Xiaomi Swings to Profit Amid Lackluster Smartphone-Industry
After Food Scandal, New Rule Requires School Officials to Dine With Students
Like the U.S., China Has Its Own College Admissions Problems
Swine Flu Prevention Moves to the Slaughterhouse

By Wang Luyao and Tang Ziyi / Feb 27, 2019 06:16 PM / Business & Tech

China’s National Medical Products Administration announced Monday that it has approved the country's first biosimilar drug — a copy of Roche’s drug Rituxan for treatment for lymphoma.

Biosimilars are nearly identical copies of biologics -- medicines made from living cells that must be stored under special conditions— already approved by a regulator.

The biosimilar drug made by Fosun Pharma’s joint venture subsidiary Shanghai Henlius Biotech will break the monopoly of Switzerland’s Roche, which has been the only supplier of Rituxan in China.

In 2017, Rituxan accounted for 1.73 billion yuan ($258.6 million) of Roche’s China sales, after the drug was added into the government-backed insurance reimbursement scheme, said Fosun Pharma in a statement.


Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.